HOME > News > Press Releases > 2023.9.28 Glac Biotech’s Totipro® PE0401 Makes History — First Postbiotic Ever to Win a NutraIngredients Award

News

2023.9.28 Glac Biotech’s Totipro® PE0401 Makes History — First Postbiotic Ever to Win a NutraIngredients Award

Share to
The celebration at Vitafoods Asia 2023 in Bangkok had barely ended when Glac Biotech received even bigger news: its Totipro® PE0401 postbiotic was crowned winner of the NutraIngredients-Asia Award for Microbiome Modulation.
Known as the “Oscars of the Nutrition Industry,” the NutraIngredients Awards spotlight only the very best in functional ingredients worldwide. For the first time ever, a postbiotic claimed the top spot in one of the award’s six functional categories. Totipro® PE0401 not only represented Asia’s first winning raw material, but also became the world’s first postbiotic to be recognized at this level.

A Breakthrough in the Postbiotic Era
This recognition builds on Glac’s long track record of international acclaim. After its flagship probiotic strain Bifidobacterium lactis CP-9 was shortlisted for “Best Weight Management Ingredient,” the success of Totipro® PE0401 affirms Glac’s leadership in both probiotics and postbiotics.
The award is proof that Glac Biotech’s research power and innovation capacity rival global giants, and that its science-based approach is redefining the health supplement industry.

The Science Behind Totipro® PE0401
Totipro® PE0401 is the only postbiotic in the world created from a blend of four carefully selected strains:
  • Lactobacillus salivarius AP-32
  • Lactobacillus acidophilus TYCA06
  • Lactobacillus plantarum LPL28
  • Bifidobacterium infantis BLI-02
After 48 hours of golden natural fermentation, the result is a rich spectrum of bioactive compounds. Studies — from in vitro models to animal research to human clinical trials — show PE0401’s ability to:
  • Strengthen intestinal barrier function
  • Enhance microbiota balance
  • Reduce digestive discomfort
  • Relieve diarrhea and promote bowel regularity
  • Regulate inflammation and immune responses
These effects make it far more impactful than single-strain postbiotics, setting a new benchmark for efficacy.

Globally Patented, Globally Recognized
With patents spanning the U.S., EU, China, Thailand, and Taiwan, Totipro® PE0401 has already been recognized for its antioxidant activity, microbiota growth promotion, and bowel health benefits. It has also won honors such as the Lactic Acid Bacteria Association Innovation Award, the National Innovation Award (Taiwan), and the China Nutrition & Health Innovation Award.
The NutraIngredients win crowns these achievements, confirming PE0401’s position as a world-class functional ingredient.

A Family of Postbiotic Innovations
While PE0401 focuses on lower digestive tract health, Glac has also developed Totipro® PE0301, targeting oral and upper digestive tract wellness. Together, they form a comprehensive postbiotic solution adaptable to multiple finished product formats, ensuring benefits for people of all ages.

A Future of Science, Quality, and Care
Glac Biotech’s success is powered by its proprietary PRONEX® probiotic powder production technology, its PRIMETEK® one-stop OEM service, and its functional verification platform for strain selection. From raw material R&D to global certification support, Glac provides partners with full-spectrum, turnkey solutions.
As CEO Sam Huang (fourth from left) and the Glac team accepted the award, the message was clear: this is not just a win for the company — it’s a leap forward for the entire field of probiotics and postbiotics.
With Totipro® PE0401, Glac Biotech has written a new chapter in health innovation. And the story is just beginning.

Media Coverage (Extended Reading)

Previous Back to list Next
Back
TOP